Drug Trial Radar · NCT00052468
Carboplatin/Paclitaxel +/-Gemcitabine in Treating Patients With Ovarian Epithelial or Fallopian Tube Cancer
Last checked: Nov 19, 2026Latest source record: Jun 25, 2014 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
1,742
Actual
Start
Aug 2002
Primary completion
Jul 2009
Study completion Jan 2011
Sponsor
- Lead sponsor
- AGO Study GroupAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Nordic Society of Gynaecological Oncology - Clinical Trials Unit; GERCOR - Multidisciplinary Oncology Cooperative Group
- First posted
- Jan 27, 2003
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Factorial
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- Female only, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells. It is not yet known whether carboplatin and paclitaxel combined with gemcitabine is more effective than carboplatin and paclitaxel alone in treating ovarian epithelial or fallopian tube cancer. PURPOSE: This randomized phase III trial is studying carboplatin and paclitaxel combined with gemcitabine to see how well it works compared to paclitaxel and carboplatin alone in treating patients who have undergone surgery for ovarian epithelial or fallopian tube cancer.
Conditions
- Fallopian Tube Cancer
- Ovarian Cancer
Interventions
TCGDrug
TCDrug
Primary outcomes
What the sponsor says the trial is designed to measure.
- Overall SurvivalTime frame: Whole Study Period
Locations
17 sites in 4 countries. Site status is shown where the registry gives one.
Herlev Hospital - University Hospital of Copenhagen
Copenhagen, Denmark
Hotel Dieu de Paris
Paris, France
Zentralkrankenhaus
Bremen, Germany
Evangelisches Krankenhaus
Düsseldorf, Germany
Universitaetsklinikum Essen
Essen, Germany
Staedtische Kliniken Frankfurt am Main - Hoechst
Frankfurt, Germany
Frauenklinik der MHH
Hanover, Germany
Vincentius Krankenhaus
Karlsruhe, Germany
University Hospital Schleswig-Holstein - Kiel Campus
Kiel, Germany
Universitaetsklinkum Magdeburg der Otto-von-Guericke-Universitaet Magdeburg
Magdeburg, Germany
Klinikum Grosshadern der Ludwig-Maximilians Universitaet Muenchen
Munich, Germany
Klinikum Rechts Der Isar - Technische Universitaet Muenchen
Munich, Germany
Klinik und Poliklinik fuer Frauenheilkunde und Geburtshilfe - Universitaetsklinikum Muenster
Münster, Germany
Universitaetsklinikum Tuebingen
Tübingen, Germany
Universitaet Ulm
Ulm, Germany
Dr. Horst-Schmidt-Kliniken
Wiesbaden, Germany
Norwegian Radium Hospital
Oslo, Norway
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.